Jennifer Hu, PhD - Director of Licensing & External Research, Merck & Co., Inc., USA
Dr. Jing-Shan Hu is currently Director of Licensing & External Research (Mainland China, Hong Kong, & Taiwan) at Merck & Co., Inc., USA. She is responsible for identifying, evaluating, and developing opportunities related to partnership, licensing-in, and acquisition for new drug candidates and technologies for drug discovery and development in Mainland China, Hong Kong, and Taiwan. Prior to joining Merck & Co., Inc. in early 2008, Dr. Hu worked with Roche Pharmaceuticals at Palo Alto as Research Leader and Head of Functional Biology following serving as the Program Leader for Toxicogenomics since 2004. Prior to that, she worked at Affymetrix in various capacities, including as Program Manager of Toxicology/Pharmacogenomics, establishing and managing programs with both pharmaceutical and academic partners to develop and demonstrate the application of Affymetrix GeneChip technology. She started her career at Human Genome Sciences as one of the founding scientists and Project Leader of VEGF-2 Protein Therapeutics program. Dr. Hu got her BS degree in Biochemistry from Peking University; PhD from Univ. of Texas & M.D. Anderson Cancer Center through CUSBEA program; her post-doctoral training at Harvard Medical School. She has authored 15 papers in peer reviewed journals such as Science, Nature Genetics, and Nature. She is also an inventor of 16 patents and patent applications. She has served as the 2006-2007 President of Sino-American Pharmaceutical Professionals Association – West (SAPA-West) and the 2002-2003 Chairperson of the Board of Peking University Alumni Association of Northern California (PKUAANC). Dr. Hu has 17 years of research, management, & business development experience with US biotech and pharmaceutical industry.
James Huang, MBA - Managing Partner, Vivo Ventures
James Huang is a Managing Partner with Vivo Ventures. He has extensive operating and business development experience through 20 years of experience in the pharmaceutical industry. He joined Vivo from Anesiva, where he served as president and previously as senior vice president of business development and commercial operations. Prior to Anesiva, he was VP Business Development and Commercial Operations at Tularik Inc. prior to its acquisition by Amgen. Mr. Huang was also a product director for diabetes at SmithKline Beecham PLC (now GlaxoSmithKline), and also held various positions in product development, business development, sales and marketing, and research and development at SmithKline Beecham, Bristol-Myers Squibb, and Alza (now a Johnson & Johnson company). He received an MBA from Stanford Graduate School of Business and earned a BS degree in Chemical Engineering at the University of California, Berkeley.
Yi Lin, PhD, MBA - Executive Director, Mingly China Growth Fund
Dr. Yi Lin is the Executive Director of Mingly China Growth Fund. He focuses on the fund’s investment and portfolio management in the healthcare sector. Prior to his current position, Dr. Lin was an entrepreneur and co-founded one of the China’s largest life science and diagnostics equipment and reagent channel companies, and led the company to raised 10 million USD venture capital from investors. Dr. Lin also worked for McKinsey & Company and provided consulting services for multinational and Chinese companies on corporate restructuring, sales and marketing, and investment strategy, and operation improvement. Dr. Lin received his BS in Biochemistry from Peking University; PhD in Microbiology and Immunology from Columbia University; and MBA from the University of Chicago.
Marc A. Schueler, MD, PhD, MBA - Director Venturing, DSM
Dr. Marc Schueler has been active in Venture Capital for more than 10 years investing in more than 40 companies and VC funds worldwide generating an overall IRR of 26%. He was a partner in 4 VC funds with a combined raised capital of more than US$ 500 million and is since 2009 located in Beijing to set-up a new Investment Vehicle for China for the Dutch Life & Material Sciences Company DSM, whose global Venture Capital program he had build up in the last 6 years. Previously he held Senior Executive Positions at Procter& Gamble and McKinsey in Europe and the USA. He is a MD graduate and qualified Eye Surgeon from the University of Heidelberg and holds a PhD from the University of Freiburg in immunology and internal medicine as well as a MBA from the University of Bradford, UK, with a specialisation in Finance.
Greg B. Scott - President and Founder, ChinaBio® LLC
Greg is an entrepreneur, angel investor and business advisor who has helped launch over thirty life science companies in the U.S. and China. He founded ChinaBio® LLC in January 2007 to identify and develop early stage life science companies in China and has helped raise over $350M in government and VC funding. ChinaBio also works with U.S. and European companies seeking partners, acquisitions and novel technologies in China. ChinaBio has organized ten investment conferences in China in just three years, and will hold its third annual ChinaBio Partnering Forum in Beijing in May, 2011. This international event will draw over 600 attendees from around the globe. Greg is also the president and co-founder of Life Science Angels, an angel investment group that has funded 32 biotechnology and medical device companies in the U.S. and China since 2005, and Executive Editor of the ChinaBio® Today newsletter. He previously held senior executive positions at Price Waterhouse, Capgemini and MCI, and was co-founder of a 200-person consulting firm. Greg lives and works in Shanghai but visits the U.S. several times a year to enjoy California’s blue sky and sandy beaches.
Stella Xu, PhD - Executive Director, Roche Partnering
Dr. Stella Xu is an Executive Director with Roche Partnering Asia. Her major responsibilities include searching potential licensing opportunities (products / technologies), and supporting transaction discussions & alliance management in Asia. Prior to her current position, Stella had held multiple global positions in Roche Partnering in the US and led more than 30 product-focused due diligence projects and alliances, including the latest two major product licensing deals in Asia. Stella joined Roche from McKinsey & Company US, a premier management consulting firm that provides strategic advices to the top management of global business leaders. At McKinsey, she led consulting engagements with global biopharmaceutical clients in areas ranging from R&D strategy, marketing & sales, to corporate development and M&A activities. Prior to McKinsey, Stella conducted biotech drug discovery work in oncology and inflammation. Stella received her PhD in Immunology and executive MBA training from Northwestern University, and her BS in Biophysics from Peking University.
Jinzi J. Wu, PhD - Vice President of HIV Drug Discovery Performance Unit, Head of Infectious Disease Discovery DMPK, GlaxoSmithKline
Dr. Jinzi J. Wu is currently Vice President, HIV drug discovery performance unit and Head of infectious disease (ID) Discovery DMPK at GlaxoSmithKline (GSK). He oversees the global HIV drug discovery from target identification and lead optimization to the preclinical and clinical development up to Phase II. Over the last two years (2009 and 2010), under Dr. Wu’s leadership, his Unit delivered two phase II clinical drugs with the best-in-class potential as well as one phase I asset. In his role as Head of ID Discovery DMPK, he supports drug discovery in other therapeutic areas such as antibacterials and anti-HCV. Dr. Wu is a co-chair or member, representing GSK, of a number of joint steering committees overseeing joint ventures and collaborations between GSK and its partners. Prior to his joining GSK in June, 2008, Dr. Wu was Vice President, Preclinical and Basic Research from 2004-2008 at Ambrilia Biopharma Inc (formerly Procyon Biopharma Inc), a biopharmaceutical company devoted to the development of anti-viral drugs. At Ambrilia, he oversaw and supported activities from the preclinical to clinical development in the areas of anti-virals and oncology. Dr. Wu was instrumental in the development of PPL-100, a clinical stage, next generation HIV protease inhibitor which was licensed to Merck in 2006 for $17 million upfront payment and milestone payments up to $215 million as well as significant royalties. From 2002-2004, Dr. Wu was Vice President, R&D at PhageTech (now Targanta Therapeutics), a biotech company discovering and developing therapeutics against infectious diseases. From 1992-2002, he held a number of senior positions, with increasing responsibilities, at Immunex (now Amgen), Novartis and Hoechst Marion Roussel (now Sanofi-Aventis). Dr. Wu has 22 years R&D experience with Big Pharma, biotechs and academic institutions. His experience in drug discovery and development involves in multiple therapeutic area with the focus on infectious diseases and oncology. He has published over 30 peer-reviewed articles and book chapters in prestigious journals and books. He is a co-inventor of 8 patent applications. He is also a regular speaker and chairperson at various US and international scientific conferences and delivered over 30 oral and poster presentations. He is a member of scientific committees of the international conferences including the International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. Dr. Wu received his PhD in Cancer Biology from the University of Arizona.
Yanning Yi, MBA - Executive Director, The Balloch Group
Yanning Yi joined TBG in 2007 and focuses on the firm's investment banking practices in the healthcare sector. Mr. Yi has worked with the healthcare team of CIBC World Markets originating IPO transactions in the US and has extensive experience on private equity deals for CRO, specialty pharma, drug discovery, and medical device companies. Prior to joining TBG, Mr. Yi worked at CIBC in Toronto where he focused on credit and investment portfolio risk management. Prior to that, Mr. Yi spent seven years with China's largest policy bank, China Development Bank, where he completed debt transactions totaling more than $3 billion in the energy, mining, manufacturing, and infrastructure industries. Mr. Yi received his MBA from the University of Western Ontario, Canada and his BA in Economics from the China Institute of Finance and Banking.
Tony Zhang, PhD - Vice President, Global External R&D, Asia, Eli Lilly and Company
Dr. Tony Zhang received his BS degree in chemistry from Shandong University. With the help of a CGP Fellowship, he obtained his PhD from Purdue University in 1989 under the direction of Professor Negishi, a 2010 Nobel laureate. After a short stint as a research scientist at Reilly Inc (now Vertellus), he joined Eli Lilly in 1992, and had led multi-disciplined teams engaged in drug development. He is recognized as a premier molecule builder, and has patented, published, and lectured extensively in synthetic chemistry, pharmaceutical process development and R&D efficiencies. He is an advisory board member for Org Process R&D, and has received a number of awards, including the highest distinction within Lilly, the Chairman Ovation Award, for his contribution to R&D productivity. Tony has been a key initiator and implementer of the company’s R&D network in China. In June 2008, he became the site head for Eli Lilly Global R&D, China, with responsibilities including development of R&D strategies, establishment and management of research collaborations, and licensing activities for molecular assets and research technologies in the Greater China area. Tony is currently serving as the board chairman for the Bayhelix Group, an association of Chinese life science business leaders with more than 300 members across US and China.
Jie Zhou, PhD, JD - Partner, Morrison & Foerster LLP
Dr. Jie Zhou is a partner in the Business Department of Morrison & Foerster's Palo Alto office. Her practice focuses on patent prosecution and counseling for clients in the areas of biotechnology, pharmaceuticals, and cleantech. She has significant experience developing worldwide patent portfolios for companies of all sizes, from start-ups to multinational corporations. She also advises clients on IP management and strategic portfolio planning. Dr. Zhou assists clients in designing patent strategies in anticipation of financings, collaborations, strategic partnering, and mergers and acquisitions. This includes advising clients in patent licensing, IP landscape reviews, and strategies for reexaminations and oppositions. She also prepares opinions (patentability, freedom-to-operate, and invalidity) and due diligence reviews for business transactions. Dr. Zhou received her BS in Biochemistry from Beijing University, her PhD in Biochemistry and Molecular Biology from University of California, Davis, and her JD from University of San Francisco.